Locilex

Locilex

Cytolex, MSI-78, pexiganan acetate Infectious disease A topical antibiotic for treating infected diabetic foot ulcers; Locilex is the first in a class of antibiotic/anti-infective magainins, derived from the skin secretions of the African clawed frog, which kill bacteria by attacking cell membranes. See Magainin. Note: It was deemed not approvable.
References in periodicals archive ?
In the fourth quarter of 2017, operating expenses also included a non-cash impairment charge of $2.3 million, or ($0.26) per share, related to the impairment of its intangible assets (trademarks and in-process research and development) acquired from Dipexium in connection with a change in operational strategy related to its Locilex assets.
(NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialisation of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, which recently announced that Locilex failed to meet the primary and secondary endpoints in its OneStep-1 and OneStep-2 Phase 3 clinical trials.
M2 PHARMA-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
The first two topical antibacterials, Innocoll's Cogenzia (gentamicin-collagen sponge) and Dipexium Pharmaceuticals' Locilex (pexiganan acetate cream 1%), are also expected to launch in the US and the five major EU markets (5EU).
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended September 30, 2016.
M2 PHARMA-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
today announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study.
Dipexium recently completed its pivotal Phase 3 clinical trials (OneStep-1 and OneStep-2) with Locilex in mild infections of diabetic foot ulcers in the United States under a Special Protocol Assessment (SPA) agreement from the US Food and Drug Administration (FDA).
Dipexium Pharmaceuticals, Inc., a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide in development for the treatment of mild infections of diabetic foot ulcers, today provided an update on the status of results from the two pivotal Phase 3 clinical trials .
M2 EQUITYBITES-February 5, 2016-Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
( ("Dipexium" or the "Company"), a late-stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a novel, broad spectrum, topical antimicrobial peptide, today announced that it has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA).
M2 EQUITYBITES-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex